Quality and Outcomes of Treatment of Hypercalcemia of Malignancy

被引：34

作者：

Wright, Jason D. ^{[1
,2
,3
]}

Tergas, Ana I. ^{[1
,2
,3
,4
]}

Ananth, Cande V. ^{[1
,4
]}

Burke, William M. ^{[1
,2
,3
]}

Hou, June Y. ^{[1
,2
,3
]}

Chen, Ling ^{[1
]}

Neugut, Alfred I. ^{[2
,3
,4
,5
]}

Richards, Catherine A. ^{[4
]}

Hershman, Dawn L. ^{[2
,3
,4
,5
]}

机构：

[1] Columbia Univ, Dept Obstet & Gynecol, New York, NY 10032 USA

[2] Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA

[3] New York Presbyterian Hosp, New York, NY USA

[4] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA

[5] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA

来源：

CANCER INVESTIGATION | 2015年 / 33卷 / 08期

关键词：

Hypercalcemia; Malignancy; Calcium; OBSTRUCTIVE PULMONARY-DISEASE; PROPENSITY SCORE METHODS; OFF-LABEL USE; LAPAROSCOPIC HYSTERECTOMY; PAMIDRONATE DISODIUM; TREATMENT FAILURE; CANCER; MORTALITY; THERAPY; CARE;

D O I：

10.3109/07357907.2015.1047506

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Using a nationwide database, 4,874 patients with hypercalcemia of malignancy were identified. The in-hospital mortality rate was 6.8%. Overall, 1,971 (40.4%) patients received pamidronate and 1,399 (28.7%) received zoledronic acid during hospitalization. Calcitonin was utilized in 1,337 (27.4%) patients while glucocorticoids were administered to 1,311 (26.9%). Use of contraindicated medications was noted in 136 (2.8%) patients who received thiazide diuretics and 12 (0.2%) who received lithium. Tumor site, presence of bone metastases, and severity of illness were predictors of treatment. There was no association between treatment with bisphosphonates, calcitonin, or glucocorticoids and morbidity or mortality.

引用

页码：331 / 339

页数：9

共 38 条

[1]

[Anonymous], 2001, ZOL AC INJ ZOM

[2]

[Anonymous], 2009, PAM DIS

[3] An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies [J].

Austin, Peter C. .

MULTIVARIATE BEHAVIORAL RESEARCH, 2011, 46 (03) :399-424

[4] Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function [J].

Berenson, JR ;

Rosen, L ;

Vescio, R ;

Lau, HS ;

Woo, M ;

Sioufi, A ;

Kowalski, O ;

Knight, RD ;

Seaman, JJ .

JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (04) :285-290

[5] The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab [J].

Castellano, Daniel ;

Manuel Sepulveda, Juan ;

Garcia-Escobar, Ignacio ;

Rodriguez-Antolin, Alfredo ;

Sundlov, Anna ;

Cortes-Funes, Hernan .

ONCOLOGIST, 2011, 16 (02) :136-145

[6] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].

CHARLSON, ME ;

POMPEI, P ;

ALES, KL ;

MACKENZIE, CR .

JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383

[7]

D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO

[8]

2-B

[9] ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].

DEYO, RA ;

CHERKIN, DC ;

CIOL, MA .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619

[10] COMPARATIVE-STUDY OF PAMIDRONATE DISODIUM AND ETIDRONATE DISODIUM IN THE TREATMENT OF CANCER-RELATED HYPERCALCEMIA [J].

GUCALP, R ;

RITCH, P ;

WIERNIK, PH ;

SARMA, PR ;

KELLER, A ;

RICHMAN, SP ;

TAUER, K ;

NEIDHART, J ;

MALLETTE, LE ;

SIEGEL, R ;

VANDEPOL, CJ .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) :134-142

← 1 2 3 4 →